# US 2026/0232790 A1 · Adjuvant formulation including low viscosity chitosan or chitosan derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232790 A1
- Document ID: US20260232790A1
- Status: Published application
- Kind: A1
- Application number: 19/151,645
- Filed: 2024-02-05
- Published: 2026-08-13
- Earliest claimed: 2023-02-07
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Erica L. Strable; David S. Thiriot; Eman Alkurdi; Colleen M. Barr
- Web page: https://patentgrep.com/patent/US20260232790A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/02: Inorganic compounds
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates generally to the use of chitosan and chitosan derivatives as an adjuvant in a vaccine composition. More specifically, the invention relates to pharmaceutical compositions and formulations that include a low viscosity chitosan or a trimethyl chitosan.

## Claims

### Claim 1

A pharmaceutical composition comprising an active biological ingredient (ABI), a chitosan or a chitosan derivative, and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is made by mixing a vaccine and the chitosan or chitosan derivative; wherein the vaccine comprises the ABI and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan that is an acid soluble chitosan.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan that is a water-soluble chitosan.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan that has a molecular weight of 5 kDa to 100 kDa.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan that has a viscosity of about 1 cP to about 125 cP at 20° C., when measured with a viscometer at 20° C. at a standard concentration.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan derivative that is a trimethyl chitosan.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan derivative that has a molecular weight greater than 100 kDa.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a chitosan derivative that has a viscosity of about 5 cP to about 30 cP at 20° C., when measured with a viscometer at 20° C. at a standard concentration.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 225 kDa and about 275 kDa.

### Claim 11 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 125 kDa and about 160 kDa.

### Claim 12 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 100 kDa and about 150 kDa.

### Claim 13 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 225 kDa and about 275 kDa and a degree of quaternization of about 30-70%.

### Claim 14 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 125 kDa and about 160 kDa and a degree of quaternization of about 40-60%.

### Claim 15 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises trimethyl chitosan having an average molecular weight of between about 100 kDa and 150 kDa and a degree of quaternization of about 50% or greater.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a salt.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a buffer present in an amount of about 1 mMol to about 100 mMol, wherein the buffer is selected from the group consisting of: acetic acid, histidine, citrate, Bis-Tris, HEPES, phosphate, MES, sodium chloride, and combinations thereof.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a tonicity modifier present in an amount of about 10 mMol to about 50 mMol, wherein the tonicity modifier is selected from the group consisting of: sodium chloride, potassium chloride, sucrose, trehalose and combinations thereof.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a detergent present in an amount of about 0.001% weight per volume (w/v) to about 0.2% (w/v), wherein the detergent is selected from the group consisting of Polysorbate 80, Polysorbate 20, Poloxamer 188, and combinations thereof.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises an aluminum adjuvant.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the ABI comprises a respiratory syncytial virus (RSV) antigen.

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the ABI comprises a recombinant RSV F trimer, wherein the RSV F trimer includes DS-Cav1 substitutions.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the ABI comprises virus-like particles (VLPs) of human papillomavirus.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein composition comprises HPV VLPs of at least one HPV type selected from the group consisting of HPV type 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73, and 82.

### Claim at position 25

25-28. (canceled)

### Claim 29 (depends on 23)

The pharmaceutical composition of claim 23, wherein the HPV VLPs comprise recombinant HPV L1 or recombinant HPV L1+L2 protein.

### Claim 30 (depends on 24)

The pharmaceutical composition of claim 24, wherein the HPV VLPs of each of the at least one HPV types are present in a concentration of about 10 μg to about 300 μg per 0.5 mL of the pharmaceutical composition, and wherein the total HPV VLP concentration is between 10 μg and 2000 μg per 0.5 mL of the pharmaceutical composition.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A method of inducing an immune response to an antigen in a human patient comprising administering to the patient the pharmaceutical composition of claim 1.

### Claim 33

A method of inducing an immune response to an antigen in a human patient comprising co-administering to the patient (a) a pharmaceutical composition comprising an ABI and (b) a chitosan or chitosan derivative.

### Claim 34 (depends on 1)

A method of preventing infection of a human patient with a pathogen comprising administering to the patient the pharmaceutical composition of claim 1, wherein the ABI comprises an antigen that is capable of eliciting an immune response directed against the pathogen.

### Claim 35

A kit comprising:
(a) a vaccine comprising an active biological ingredient (ABI); and
(b) a chitosan or a chitosan derivative.

### Claim 36 (depends on 35)

The kit of claim 35, further comprising instructions for administering to a human patient the vaccine and the chitosan or chitosan derivative.

### Claim 37

A method of inducing a neutralizing immune response against an antigen in a patient in need thereof comprising:
administering to the patient a pharmaceutical composition comprising:
a chitosan or chitosan derivative, and
an active biological ingredient (ABI) comprising an antigen,
whereby the administration of the pharmaceutical composition induces a neutralizing immune response against the antigen in the patient.
